Company Overview
Soligenix, Inc. operates as a late-stage biopharmaceutical entity dedicated to the development and commercialization of therapeutic products specifically designed to address rare diseases within the United States market. The company functions within the broader Healthcare sector, specifically targeting the Biotechnology industry, which implies a focus on high-risk, high-reward research and development activities aimed at unmet medical needs. Currently, the organization maintains a relatively small operational footprint with a workforce consisting of 14 employees, supported by a total market capitalization of $11.40M. The combination of a $11.40M market cap and an annual revenue figure that results in a price-to-sales ratio of infinity suggests the company is in a pre-revenue or negligible revenue stage, indicating its position as a micro-cap entity where valuation is driven primarily by potential asset value and clinical pipeline prospects rather than current earnings generation or sales volume.
Financial Health
The company's financial performance over the trailing twelve months is characterized by significant operational losses, with reported revenue, net income, and EBITDA figures listed as N/A or negative, specifically showing a net income of $-11,171,557 and an EBITDA of $-12,080,094. The substantial gap between the reported revenue status (effectively zero for valuation purposes given the infinite P/S) and the negative net income of approximately $11.17 million reveals a cost structure dominated by heavy research and development expenditures and general administrative costs typical of late-stage biotechnology firms before commercial product launch. Free cash flow stands at $-5,953,901, which indicates that the company is burning cash at a rate that requires ongoing financing to sustain operations and advance its development programs. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting a business model where revenue has not yet covered the direct costs of goods sold or operating expenses sufficiently to generate profitability. On the balance sheet, the company holds $10.53M in cash against $385,054 in debt, resulting in a debt-to-equity ratio of 5.07, which suggests a leveraged capital structure relative to equity but highlights a strong liquidity buffer provided by the cash hoard. The current ratio of 3.18 indicates a robust short-term liquidity position, as the company possesses more than three times the liquid assets required to meet its short-term obligations. Return on equity is reported at -165.1% and return on assets at -69.4%, metrics that reveal management is currently deploying capital to achieve future growth rather than generating immediate returns on the invested equity and assets.
Valuation Assessment
Valuation multiples for Soligenix reflect its status as an unprofitable growth entity, with a trailing P/E ratio listed as N/A and a forward P/E of -1.33. The discrepancy between a non-existent trailing earnings multiple and a negative forward P/E implies that the market is pricing in future earnings potential that has not yet materialized in current financial statements. The price-to-book ratio stands at 1.47, indicating that the market values the company at 47% above its book value, which often suggests investor confidence in the intangible value of the intellectual property and clinical pipeline despite the lack of current profits. Alternative valuation metrics such as the price-to-sales ratio of infinity and an EV/EBITDA of -0.10 further illustrate that traditional profitability-based valuation methods are inapplicable, forcing reliance on asset-based or pipeline-driven valuations. The stock has exhibited significant price volatility, trading between a 52-week high of $6.23 and a 52-week low of $1.02, with the current trading position situated at a specific point within this range that reflects the binary nature of biotech investing. The beta of 2.03 indicates that the stock price is twice as volatile as the broader market, meaning that price movements in Soligenix are expected to be amplified relative to general market shifts, increasing both the potential for rapid appreciation and the risk of sharp declines.
Growth & Income
Regarding growth metrics, the company reports revenue growth year-over-year as N/A and earnings growth year-over-year as N/A, as the financial data does not support a historical growth trajectory due to the lack of sustained revenue. Since the earnings growth rate is not applicable, a direct comparison between earnings and revenue growth rates is not possible, but the negative earnings figure implies that the company is prioritizing capital expenditure over profit generation. Soligenix does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the company reinvests all available resources, including its $10.53M cash reserve, directly into research and development activities rather than distributing income to shareholders. The overall growth and income profile for Soligenix is defined by a reinvestment strategy typical of pre-commercial biotechnology firms, where the absence of dividends and current profitability underscores a focus on long-term product development rather than short-term income generation or shareholder yield.